Healthy Aging and Dementia: Two Roads Diverging in Midlife?
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Dementia, particularly Alzheimer's disease (AD), is a growing pandemic that presents profound challenges to healthcare systems, families, and societies throughout the world. By 2050, the number of people living with dementia worldwide could almost triple, from 47 to 132 million, with associated costs rising to $3 trillion. To reduce the future incidence of dementia, there is an immediate need for interventions that target the disease process from its earliest stages. Research programs are increasingly starting to focus on midlife as a critical period for the beginning of AD-related pathology, yet the indicators of the incipient disease process in asymptomatic individuals remain poorly understood. We address this important knowledge gap by examining evidence for cognitive and structural brain changes that may differentiate, from midlife, healthy aging and pathological AD-related processes. This review crystallizes emerging trends for divergence between the two and highlights current limitations and opportunities for future research in this area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Mapping cortical change across the human life span
Sowell, E. R., Peterson, B. S., Thompson, P. M., Welcome, S. E., Henkenius, A. L., & Toga, A. W. (2003) · Nature Neuroscience · doi:10.1038/nn1008 · Cited by 2,328
Insights into the ageing mind: a view from cognitive neuroscience
Hedden, T., & Gabrieli, J. D. E. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1323 · Cited by 2,223
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925 · cited 1×
“…research efforts are increasingly focusing on preclinical AD – those at risk based on genetic and/or family history factors, but not yet showing symptoms – in order to detect early biomarkers, monitor progression, and employ disease-modifying agents as they become available (Dubois et al., 2016).”
BackgroundProtective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920 · cited 1×
“…the ε4 allele imposes a greater risk of developing AD compared to the ε3 allele, increasing in a dose dependent manner from 20 to 90% in homozygous carriers (Corder et al., 1993), whereas the ε2 allele has been suggested to provide a protective effect, lowering the risk of AD (Corder et al., 1994).”
BackgroundFrequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656 · cited 1×
“…to the disorder may have already begun an irreversible trajectory of neurodegeneration by the stage of MCI, as several studies suggest that dementia’s pathology may be present years or even decades before its clinical diagnosis (Braak and Braak, 1997; Jack et al., 2009; Ritchie et al., 2015).”
BackgroundLongitudinal Magnetic Resonance Imaging Studies of Older Adults: A Shrinking Brain
Resnick, S. M., Pham, D. L., Kraut, M. A., Zonderman, A. B., & Davatzikos, C. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-08-03295.2003 · Cited by 1,425
Diffusion tensor imaging of white matter tract evolution over the lifespan
Lebel, C., Gee, M., Camicioli, R., Wieler, M., Martin, W., & Beaulieu, C. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.11.094 · Cited by 1,100
Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review
Ford, J. G., Howerton, M. W., Lai, G. Y., Gary, T. L., Bolen, S., Gibbons, M. C., Tilburt, J., Baffi, C., Tanpitukpongse, T. P., Wilson, R. F., et al. (2008) · Cancer · doi:10.1002/cncr.23157 · Cited by 1,083
Executive Functioning as a Potential Mediator of Age-Related Cognitive Decline in Normal Adults.
Salthouse, T. A., Atkinson, T. M., & Berish, D. E. (2003) · Journal of Experimental Psychology: General · doi:10.1037/0096-3445.132.4.566 · Cited by 1,057
Rönnlund, M., Nyberg, L., Bäckman, L., & Nilsson, L.-G. (2005) · Psychology and Aging · doi:10.1037/0882-7974.20.1.3 · Cited by 839
Life-Span Changes of the Human Brain White Matter: Diffusion Tensor Imaging (DTI) and Volumetry
Westlye, L. T., Walhovd, K. B., Dale, A. M., Bjornerud, A., Due-Tonnessen, P., Engvig, A., Grydeland, H., Tamnes, C. K., Ostby, Y., & Fjell, A. M. (2010) · Cerebral Cortex · doi:10.1093/cercor/bhp280 · Cited by 765
Head, D. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhh003 · Cited by 645
Bateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., Salloway, S., Sperling, R. A., Windisch, M., & Xiong, C. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt59 · Cited by 573 · cited 2×
“Less than 1% of cases are attributable to familial AD (Bateman et al., 2010), which is passed on from parents to children through mutations in specific genes (Bateman et al., 2010) and is associated with an earlier onset compared with sporadic AD (typically between ages 50 and 65, compared with…”
BackgroundAging of cerebral white matter: a review of MRI findings
Gunning‐Dixon, F. M., Brickman, A. M., Cheng, J. C., & Alexopoulos, G. S. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2087 · Cited by 564
Storsve, A. B., Fjell, A. M., Tamnes, C. K., Westlye, L. T., Overbye, K., Aasland, H. W., & Walhovd, K. B. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0391-14.2014 · Cited by 542
Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI
Jack, C. R., Shiung, M. M., Weigand, S. D., O’Brien, P. C., Gunter, J. L., Boeve, B. F., Knopman, D. S., Smith, G. E., Ivnik, R. J., Tangalos, E. G., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000180958.22678.91 · Cited by 492
Human cognitive aging: Corriger la fortune?
Lindenberger, U. (2014) · Science · doi:10.1126/science.1254403 · Cited by 414 · cited 4×
“…has been reported within this range (Fraser et al., 2015; Leong et al., 2017), yet the age-related hippocampal volume reductions shown in several longitudinal studies (Raz et al., 2005; Fraser et al., 2015; Leong et al., 2017) fail to reach the high rates reported in AD (Lindenberger, 2014).”
BackgroundResultInfluentialA meta-analysis of diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease
Sexton, C. E., Kalu, U. G., Filippini, N., Mackay, C. E., & Ebmeier, K. P. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.019 · Cited by 410
Self-citationWhite matter damage in frontotemporal dementia and Alzheimer's disease measured by diffusion MRI
Zhang, Y., Schuff, N., Du, A.-T., Rosen, H. J., Kramer, J. H., Gorno-Tempini, M. L., Miller, B. L., & Weiner, M. W. (2009) · Brain · doi:10.1093/brain/awp071 · Cited by 356 · cited 13×
“For example, Head et al. (2004) demonstrated a dissociation between normal and pathological aging in a DTI study of young adults, cognitively healthy older adults, and older adults with AD, where ageassociated decline in white matter integrity was apparent in anterior brain regions, while AD-related effects were obser…”
BackgroundResultInfluentialAPOE ε4: The most prevalent yet understudied risk factor for Alzheimer's disease
Michaelson, D. M. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.015 · Cited by 331
Genetics of familial and sporadic Alzheimer s disease
Piaceri, I. (2013) · Frontiers in Bioscience · doi:10.2741/e605 · Cited by 256
Visual memory predicts Alzheimer's disease more than a decade before diagnosis
Kawas, C. H., Corrada, M. M., Brookmeyer, R., Morrison, A., Resnick, S. M., Zonderman, A. B., & Arenberg, D. (2003) · Neurology · doi:10.1212/01.wnl.0000055813.36504.bf · Cited by 247
Lexical Retrieval in Healthy Aging
Nicholas, M., Obler, L., Albert, M., & Goodglass, H. (1985) · Cortex · doi:10.1016/s0010-9452(58)80007-6 · Cited by 224
Salthouse, T. A. (2014) · Current Directions in Psychological Science · doi:10.1177/0963721414535212 · Cited by 174
Bartzokis, G., Lu, P. H., Heydari, P., Couvrette, A., Lee, G. J., Kalashyan, G., Freeman, F., Grinstead, J. W., Villablanca, P., Finn, J. P., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.07.010 · Cited by 152
Johnson, S. C., La Rue, A., Hermann, B. P., Xu, G., Koscik, R. L., Jonaitis, E. M., Bendlin, B. B., Hogan, K. J., Roses, A. D., Saunders, A. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.11.012 · Cited by 112 · cited 9×
“An interpretation of these relative increases is that they may serve to sustain normal cognition despite the gray matter reductions of the prefrontal, parietal, and temporal regions in APOE ε4 carriers (Alexander et al., 2012).”
BackgroundInfluentialAdluru, N., Destiche, D. J., Lu, S. Y.-F., Doran, S. T., Birdsill, A. C., Melah, K. E., Okonkwo, O. C., Alexander, A. L., Dowling, N. M., Johnson, S. C., et al. (2014) · NeuroImage: Clinical · doi:10.1016/j.nicl.2014.04.008 · Cited by 85
Effects of APOE on brain white matter microstructure in healthy adults
Westlye, L. T., Reinvang, I., Rootwelt, H., & Espeseth, T. (2012) · Neurology · doi:10.1212/wnl.0b013e3182735c9c · Cited by 84
Cited by
Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia
Connell, E., Le Gall, G., Pontifex, M. G., Sami, S., Cryan, J. F., Clarke, G., Müller, M., & Vauzour, D. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00548-6 · Cited by 208
“Here, individuals are more likely to experience reductions in gray matter in the dorsolateral and medial prefrontal, parietal, and lateral temporal regions [40, 41], alongside a loss of white matter integrity in the cingulum, corpus callosum, and superior longitudinal fasciculus [42–44].”
BackgroundStara, V., Vera, B., Bolliger, D., Rossi, L., Felici, E., Di Rosa, M., de Jong, M., & Paolini, S. (2020) · JMIR mHealth and uHealth · doi:10.2196/25891 · Cited by 36
Zarate, S. M., Huntington, T. E., Bagher, P., & Srinivasan, R. (2023) · npj Aging · doi:10.1038/s41514-023-00102-8 · Cited by 19
“Advanced age is the single greatest risk factor for neurodegenerative conditions such as Parkinson’s disease (PD), Alzheimer’s disease (AD) (Hou et al., 2019), stroke (Leritz et al., 2011; Yousufuddin and Young, 2019), and dementia (Irwin et al., 2018).”
BackgroundHeneghan, A., Deng, F., Wells, K., Ritchie, K., Muniz-Terrera, G., Ritchie, C. W., Lawlor, B., & Naci, L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220267 · Cited by 18
Metadata
- Authors
- Irwin, K., Sexton, C., Daniel, T., Lawlor, B., & Naci, L.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2018-09-19
- Volume
- 10
- Pages
- 275-275
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2891170853
- Cited by
- 124
- References
- 32
- FWCI
- 7.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.